Sponsored by
Latest
Topics
Topics
Accounting & Tax
Corporate Finance
Human Capital
Risk & Compliance
Strategy
Technology
Featured
Technology
CFOs Vow to Boost Tech Influence in 2023
Greater vigilance in overseeing technology strategy shapes up as a key priority for the coming year.
By
David McCann
| February 6, 2023
Read More
Resources
CFO Live
2022 Survey
Sign Up
Menu
Topics
Accounting & Tax
Corporate Finance
Human Capital
Risk & Compliance
Strategy
Technology
Explore
Search
Latest
Resources
CFO Live
2022 Survey
Sign Up
Sponsored by
vaccine
Strategy
Anheuser-Busch Pulls Budweiser Super Bowl Ads
The beer giant said it would redirect funds to vaccine outreach.
By
Lauren Muskett
| January 26, 2021
Read More
Credit & Capital
AMC Raises $917 Million to Keep Theaters Open
The new equity and debt capital "means that any talk of an imminent bankruptcy for AMC is completely off the table."
By
Matthew Heller
| January 26, 2021
Read More
Risk & Compliance
Merck Drops Out of COVID-19 Vaccine Race
Merck's announcement that it is shelving its two vaccine candidates "marks a shocking setback for one of the most storied vaccine makers."
By
Matthew Heller
| January 25, 2021
Read More
Human Capital & Careers
United Airlines CEO Backs Vaccine Mandate for Workers
"I think the right thing to do is for United Airlines, and for other companies, to require [COVID] vaccines."
By
Matthew Heller
| January 22, 2021
Read More
The Economy
U.S. Loses 140,000 Jobs Amid New Lockdowns
The December jobs report shows "the economy’s not just tapping on the brakes, but actually has been thrown into reverse."
By
Matthew Heller
| January 8, 2021
Read More
Financial Performance
Moderna Q3 Revenues Beat Estimates
The biotech is preparing for the global launch of its potential COVID-19 vaccine.
By
Lauren Muskett
| October 29, 2020
Read More
Risk & Compliance
Be Ready to Distribute COVID-19 Vaccine in Two Months, CDC Says
Public health authorities were notified to prepare to distribute a coronavirus vaccine as early as late October.
By
Lauren Muskett
| September 3, 2020
Read More
M&A
AstraZeneca Inks COVID-19 Vaccine Supply Deal
The pharma giant agreed to pay Oxford Biomedica $20 million to reserve 1,000 liters of production capacity.
By
Lauren Muskett
| September 1, 2020
Read More
Risk & Compliance
Pfizer, BioNTech to Supply U.S. Government Up to 600M Doses of Coronavirus Vaccine
The initial 100 million doses ordered is valued at $1.95 billion.
By
Lauren Muskett
| July 22, 2020
Read More
Risk & Compliance
J&J Speeds Up Timeline for Coronavirus Vaccine
After lagging behind other companies, J&J now expects to begin a late-stage study of its vaccine candidate in September.
By
Matthew Heller
| July 16, 2020
Read More
M&A
Merck Enters Race to Develop COVID Vaccine
The world's largest vaccine maker is no longer on the COVID sidelines after acquiring an Austrian biotech and teaming up with a nonprofit.
By
Matthew Heller
| May 26, 2020
Read More
Risk & Compliance
Moderna Stock Soars on COVID Vaccine Results
Interim data from a Phase 1 study showed Moderna's vaccine candidate stimulated an immune response against the virus in people.
By
Matthew Heller
| May 18, 2020
Read More
Risk & Compliance
Moderna Gets $483M to Fund Corona Vaccine
The grant from the U.S. government will boost Moderna's efforts to develop what is “among the most advanced coronavirus vaccine candidates.”
By
Matthew Heller
| April 17, 2020
Read More